Midostaurin

{
  "id": "MLC-T-ONC-005377",
  "term": "Midostaurin",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used alone or with other anticancer drugs to treat adults with certain types of acute myeloid leukemia, mast cell leukemia, or systemic mastocytosis. It is also being studied in the treatment of other types of cancer. Midostaurin blocks certain proteins, which may help keep cancer cells from growing and may kill them. It may also prevent the growth of new blood vessels that tumors need to grow. Midostaurin is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called N-benzoyl-staurosporine, PKC412, and Rydapt.",
    "A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors."
  ],
  "synonyms": [
    "N-benzoyl-staurosporine",
    "PKC412",
    "Rydapt",
    "N-benzoylstaurosporine"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/midostaurin/"
}